We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+32.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$343M
AUM Growth
+$158M
Cap. Flow
+$103M
Cap. Flow %
29.91%
Top 10 Hldgs %
65.57%
Holding
72
New
18
Increased
24
Reduced
6
Closed
20
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$17.6M
2
AMRN icon
Amarin Corp
AMRN
+$14.4M
3
DHR icon
Danaher
DHR
+$12.8M
4
EHTH icon
eHealth
EHTH
+$11.1M
5
GSK icon
GSK
GSK
+$10.9M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$5.19M
2
MRK icon
Merck
MRK
+$3.53M
3
ZGNX
Zogenix, Inc.
ZGNX
+$3.24M
4
TSRO
TESARO, Inc.
TSRO
+$2.67M
5
ABT icon
Abbott
ABT
+$2.27M

Sector Composition

Rank Sector Weight
1 Healthcare 86.25%
2 Industrials 8.36%
3 Financials 3.65%
4 Miscellaneous 1.46%
5 Real Estate 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TLGT
26
DELISTED
Teligent, Inc
TLGT
$2.99M 0.87%
257,488
+32,740
+15% +$494K
2017 Q4
5 quarters
IRWD icon
27
Ironwood Pharmaceuticals
IRWD
$585M
$2.65M 0.77%
+233,667
New +$2.61M
2019 Q1
0 quarters
DERM icon
28
DELISTED
Dermira, Inc.
DERM
$2.43M 0.71%
+179,500
New +$1.5M
2019 Q1
0 quarters
XENE icon
29
Xenon Pharmaceuticals
XENE
$3.25B
$2.28M 0.66%
224,340
+19,236
+9% +$163K
2018 Q3
2 quarters
MDCO
30
DELISTED
Medicines Co
MDCO
$2.13M 0.62%
+76,200
New +$1.8M
2019 Q1
0 quarters
APLS icon
31
DELISTED
Apellis Pharmaceuticals
APLS
$2.03M 0.59%
104,349
-2,531
-2% -$39.8K
2018 Q2
3 quarters
TCDA
32
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.91M 0.56%
49,508
+8,986
+22% +$209K
2018 Q3
2 quarters
MYOK
33
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.82M 0.53%
+35,052
New +$1.61M
2019 Q1
0 quarters
CHRS icon
34
Coherus Oncology
CHRS
$155M
$1.64M 0.48%
+120,036
New +$1.6M
2019 Q1
0 quarters
CRSP icon
35
CRISPR Therapeutics
CRSP
$4.75B
$1.51M 0.44%
+42,400
New +$1.47M
2019 Q1
0 quarters
CBAY icon
36
DELISTED
Cymabay Therapeutics
CBAY
$1.42M 0.42%
107,296
+60,200
+128% +$640K
2018 Q2
3 quarters
AFMD icon
37
DELISTED
Affimed
AFMD
$1.35M 0.39%
32,217
-1,360
-4% -$48.9K
2018 Q1
4 quarters
CNC icon
38
Centene
CNC
$34.2B
$1.25M 0.37%
23,600
+15,000
+174% +$911K
2018 Q1
4 quarters
FOMX
39
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.1M 0.32%
294,660
– –
2018 Q1
4 quarters
CTRE icon
40
CareTrust REIT
CTRE
$8.61B
$977K 0.28%
41,264
-10,000
-20% -$219K
2017 Q4
5 quarters
EIGR
41
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$975K 0.28%
+2,324
New +$933K
2019 Q1
0 quarters
IVC
42
DELISTED
Invacare Corporation
IVC
$662K 0.19%
79,081
+5,179
+7% +$37.3K
2017 Q4
5 quarters
DRNA
43
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$602K 0.18%
41,074
– –
2018 Q2
3 quarters
ALBO
44
DELISTED
Albireo Pharma Inc
ALBO
$581K 0.17%
18,029
– –
2018 Q1
4 quarters
CNCE
45
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$569K 0.17%
+47,154
New +$695K
2019 Q1
0 quarters
HSKA
46
DELISTED
Heska Corp
HSKA
$569K 0.17%
+6,680
New +$602K
2019 Q1
0 quarters
OTIC
47
DELISTED
Otonomy, Inc.
OTIC
$474K 0.14%
+180,100
New +$406K
2019 Q1
0 quarters
PFNX
48
DELISTED
Pfenex Inc.
PFNX
$468K 0.14%
+75,700
New +$331K
2019 Q1
0 quarters
OPCH icon
49
Option Care Health
OPCH
$4.67B
$246K 0.07%
+30,753
New +$404K
2019 Q1
0 quarters
NGNE icon
50
Neurogene
NGNE
$465M
$199K 0.06%
3,686
– –
2018 Q4
1 quarter
1
2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Eversept Partners held 72 positions worth $343M, up 86% from $185M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Eversept Partners deployed $103M of net new capital in Q1 2019, opening 18 new positions and adding to 24 existing holdings. Its largest new stake was NuVasive, Inc.: 330,601 shares worth $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Aerie Pharmaceuticals, an estimated $5.19M trimmed.

  • Eversept Partners's largest Q1 2019 buy was NuVasive, Inc.: 330,601 shares worth $18.8M.
  • Eversept Partners added most to Amarin Corp in Q1 2019, an estimated $14.4M increase.
  • Eversept Partners's biggest Q1 2019 reduction was Aerie Pharmaceuticals, cutting an estimated $5.19M.
  • Eversept Partners fully exited Merck in Q1 2019, selling an estimated $3.53M.
  • Eversept Partners's ten largest holdings make up 66% of its $343M portfolio in Q1 2019.
  • Eversept Partners opened 18 new positions and closed 20 in Q1 2019.
  • Eversept Partners's portfolio value rose 86% quarter-over-quarter to $343M.

Based on Eversept Partners's 13F filing for Q1 2019, filed 14 May 2019.